Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,440 | 2,520 | 03.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.06. | Sonoma Pharmaceuticals GAAP EPS of -$0.48, revenue of $3.75M | 4 | Seeking Alpha | ||
17.06. | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | 354 | ACCESS Newswire | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
17.06. | Sonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
17.06. | Sonoma Pharmaceuticals, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
28.04. | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
22.04. | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain | 371 | ACCESS Newswire | BOULDER, CO / ACCESS Newswire / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
SONOMA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
07.04. | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
11.03. | What's Going On With Sonoma Pharmaceuticals Stock Tuesday? | 9 | Benzinga.com | ||
11.03. | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | 661 | AFX News | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
10.03. | Sonoma Pharmaceuticals expands into UK market | 9 | Investing.com | ||
10.03. | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency | 409 | ACCESS Newswire | BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
10.03. | Sonoma Pharmaceuticals Stock Surges 39% On Upcoming AAD Annual Meeting Exhibit | 2 | RTTNews | ||
25.02. | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando | 384 | ACCESS Newswire | BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
05.02. | Sonoma Pharmaceuticals GAAP EPS of -$0.63 beats by $0.06, revenue of $3.6M misses by $0.46M | 5 | Seeking Alpha | ||
05.02. | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results | 365 | ACCESS Newswire | Revenues increased 14% for the quarter compared to prior year and 13% year-to-datePositive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024Year-to-date net loss... ► Artikel lesen | |
05.02. | Sonoma Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
30.01. | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
05.12.24 | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices | 350 | ACCESS Newswire | BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
21.11.24 | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States | 417 | ACCESS Newswire | BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 42,250 | -0,33 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Fresenius auf "Buy" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen festgestellt... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 47,540 | -0,71 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat FMC auf "Neutral" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen festgestellt... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,530 | -0,85 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Siemens Healthineers auf "Overweight" mit einem Kursziel von 60,50 Euro belassen. Die Ende Juli anstehenden Zahlen für das laufende, dritte Geschäftsquartal... ► Artikel lesen | |
CARL ZEISS MEDITEC | 53,70 | -0,28 % | UBS stuft CARL ZEISS MEDITEC AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Carl Zeiss Meditec auf "Neutral" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen... ► Artikel lesen | |
ECKERT & ZIEGLER | 66,40 | -0,60 % | Eckert&Ziegler mit BLITZMELDUNG: Eigener Vorstand kauft massiv Anteile - Das dürfen Sie auf keinen Fall verpassen! | ||
DRAEGERWERK | 65,40 | -0,91 % | Dräger-Aktie legt um 0,15 Prozent zu (67,10 €) | Im deutschen Wertpapierhandel liegt das Wertpapier von Dräger zur Stunde im Plus. Der jüngste Kurs betrug 67,10 Euro. Das Wertpapier von Dräger verzeichnet aktuell ein Kursplus von 0,15 Prozent. Es... ► Artikel lesen | |
MEDTRONIC | 74,50 | -0,90 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
INTUITIVE SURGICAL | 460,65 | -0,46 % | Intuitive Surgical stock gains as DV5 receives early CE mark approval | ||
UNITEDHEALTH | 261,85 | -0,38 % | Neue Anleihe von UnitedHealth: A2-Rating, 5,3% Kupon | Stuttgart (www.anleihencheck.de) - Die UnitedHealth Group (ISIN US91324P1021/ WKN 869561) emittiert eine neue Unternehmensanleihe (ISIN US91324PFQ00/ WKN A4EC5N) im Umfang von 1 Mrd. Euro, so die Börse... ► Artikel lesen | |
GERRESHEIMER | 48,620 | -0,45 % | BASF, Gerresheimer, Puma, Renk Group, Suss MicroTec, TUI - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
TELADOC HEALTH | 7,034 | +0,26 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
THERMO FISHER | 365,00 | -0,52 % | Here's What to Expect From Thermo Fisher Scientific's Next Earnings Report | ||
STRATEC | 26,700 | -0,93 % | EQS-News: STRATEC SE: Hauptversammlung beschliesst Dividendenausschüttung in Höhe von 0,60 € je Aktie | EQS-News: STRATEC SE
/ Schlagwort(e): Hauptversammlung
STRATEC-HAUPTVERSAMMLUNG BESCHLIESST DIVIDENDENAUSSCHÜTTUNG IN HÖHE VON 0,60 € JE AKTIE
27.06.2025... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 13,520 | -0,66 % | Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition | Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 membersExceeds high-end of Q1 guidance on membership... ► Artikel lesen | |
NUTEX HEALTH | 116,79 | -4,50 % | Nutex Health, Inc.: Nutex Health Reports First Quarter 2025 Financial Results | TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8%
NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET... ► Artikel lesen |